ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN is extremely Undervalued

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Aug 31, 2021 8:41am

136 Views

Post# 33786942

RE:RE:PMN is extremely Undervalued

NanCY, I am 100% Long and have been holding onto PMN for over a Year. I got extremely lucky to have stumbled upon PMN when it was at 0.10.

PMN has such great Potential that I keep buying when it Dips, anywhere from 0.10 to 0.22.

I am too deeply invested to cash out now, I want to wait until we hit it big!

Sorry if I seem to be all over the map but I guess this is the only Stock that does that for me which makes it quite intriquing.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks